Values First Advisors Inc. Buys 1,419 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,412 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,419 shares during the quarter. Values First Advisors Inc. owned about 0.06% of Collegium Pharmaceutical worth $711,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its stake in shares of Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after acquiring an additional 499,473 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after acquiring an additional 17,942 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 8.2% during the 2nd quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock worth $54,124,000 after acquiring an additional 128,003 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after acquiring an additional 113,300 shares in the last quarter.

Collegium Pharmaceutical Trading Down 4.4 %

Shares of COLL opened at $34.31 on Friday. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $42.29. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. The stock has a 50 day simple moving average of $37.67 and a 200-day simple moving average of $35.38. The stock has a market cap of $1.12 billion, a PE ratio of 14.30 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the prior year, the firm posted $1.13 EPS. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the subject of several recent analyst reports. Truist Financial increased their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. HC Wainwright raised their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.